Anti-VEGFA Antibody [Bevacizumab] (A279816)

Anti-VEGFA Antibody [Bevacizumab]

Human monoclonal [Bevacizumab] antibody to VEGFA.

Human

Human VEGF.

Human

Monoclonal

Bevacizumab

IgG1

Protein A affinity chromatography.

1 mg/ml

>98% (by SDS-PAGE).

Supplied in Phosphate Buffered Saline with 0.02% ProClin 300.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Human Anti-VEGF antibody is a research grade biosimilar of the monoclonal antibody drug bevacizumab. This product is supplied in a research grade format, i.e. in PBS buffer with preservative, it is not manufactured or formulated in the same way as the therapeutic reference product. A preservative free version is available on request. This product is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic bevacizumab antibody clone. This antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-bevacizumab antibodies, for example HCA182 and HCA185. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-bevacizumab antibody in IgG1 format as a reference standard, for example HCA184 or HCA185. Bevacizumab, also known as Avastin, is a humanized monoclonal antibody (IgG1 kappa) that inhibits angiogenesis by binding to VEGF-A. VEGF-A stimulates new blood vessel formation in certain diseases, especially in cancer. Avastin is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian. This product is NOT FOR THERAPEUTIC USE. View a summary of supporting anti-bevacizumab antibody products.

L-VEGF, Vascular endothelial growth factor A, long form, Vascular permeability factor, VEGF, VPF